Nafamostat (mesylate)

Nafamostat (mesylate)

• CAS Number: 82956-11-4
• UNSPSC Description: Nafamostat mesylate (FUT-175), an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat mesylate has anticancer and antivirus effect. Nafamostat mesylate induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1). Nafamostat mesylate can be used in the development of the pathological thickening of the arterial wall[1][2][3][4].
• Target Antigen: Apoptosis; Flavivirus; NF-κB; Ser/Thr Protease; TNF Receptor
• Type: Reference compound
• Related Pathways: Anti-infection;Apoptosis;Metabolic Enzyme/Protease;NF-κB
• Applications: COVID-19-anti-virus
• Field of Research: Cancer; Infection
• Assay Protocol: https://www.medchemexpress.com/nafamostat-mesylate.html
• Purity: 99.97
• Solubility: DMSO : 50 mg/mL (ultrasonic)|H2O : 33.33 mg/mL (ultrasonic)
• Smiles: CS(=O)(O)=O.O=C(OC1=CC=C2C=C(C(N)=N)C=CC2=C1)C3=CC=C(NC(N)=N)C=C3.CS(=O)(O)=O
• Molecular Weight: 539.58
• References & Citations: [1]Uwagawa T, et al. Mechanisms of synthetic serine protease inhibitor (FUT‐175)‐mediated cell death [J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2007, 109(10): 2142-2153.|[2]Tajima H, et al. Enhanced invasiveness of pancreatic adenocarcinoma cells stably transfected with cationic trypsinogen cDNA [J]. International journal of cancer, 2001, 94(5): 699-704.|[3]Yan Y, et al. Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins [J]. Antiviral research, 2022, 202: 105325.|[4]Sawada M, et al. Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats [J]. Stroke, 1999, 30(3): 644-650.Antiviral Res. 2023 Apr 17;105606.|bioRxiv. 2024 October 09.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Cell Res. 2020 Mar;30(3):269-271.|Eur J Pharmacol. 2022 Feb 2;174795.|Eur J Pharmacol. 2022 Nov 17;175394.|Nat Chem Biol. 2022 Jun 8.|Nat Commun. 2024 Jun 27;15(1):5458.|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Viruses. 2022, 14(9), 2017.|Biomolecules. 2022, 12(8), 1063.|Cells. 2022, 11(3), 319.|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Patent. US20230210807A1.|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture and light)
• Clinical Information: Launched